Merck KGaA Expands Head and Neck Cancer Therapy Portfolio with Debiopharm’s Xevinapant
By Debadrita Paul & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)
Published: 2 Apr-2021
DOI: 10.3833/pdr.v2021.i4.2603 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its interest in the head and neck cancer treatment space, Merck KGaA has agreed to in-license the worldwide rights to Debiopharm’s xevinapant, a potentially first-in-class inhibitor of apoptosis proteins antagonist...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS